Study finds no link between canagliflozin, fracture risk in diabetes R

Researchers used a cohort of 159,928 patients with type 2 diabetes, mean age of 55, and found that both canagliflozin and GLP-1 receptor agonist users had similar event rates for forearm, hip, humerus or pelvis fracture requiring intervention, with an overall hazard ratio of 0.98. The findings in the Annals of Internal Medicine revealed that users of the drugs also had a similar risk for ankle, carpal, hip, humerus, metacarpal, metatarsal, pelvic, radius or ulna fracture.

Physician’s Briefing/HealthDay News (1/2)